Tag: ACADIA Pharmaceuticals

October 15, 2019

Pharma Market Update: Q3 2019 in Review

With Q3 2019 officially over, the Investing News Network shares a pharma market update on the biggest news and trends...
October 31, 2018

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial

ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD)...
August 7, 2018

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Neuren Pharmaceuticals (ASX:NEU) announced today that they have entered into an exclusive North American License Agreement...
July 10, 2018

Pharmaceutical Update: Q2 2018 in Review

With Q2 officially behind us and Q3 already in full swing, here the Investing News Network is providing a look...
June 29, 2018

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID (Pimavanserin)

ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID...
February 19, 2018

5 Top Performing Life Science ETFs

Who are the top performing ETFs in the pharmaceuticals, biotechnology and life sciences markets year-to-date?
November 15, 2016

ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients

ACADIA Pharmaceuticals, a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today...